You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Roxindole hydrochloride
Roxindole hydrochloride is a dopamine D2 autoreceptor agonist, with affinity for D3, D4 and 5-HT1 receptors (pKi values are 8.55, 8.93, 8.23, 9.42, 6.00 and 7.05 for human D2, D3, D4, 5-HT1A, 5-HT1B and 5-HT1D receptors). Inhibits 5-HT uptake and is antidepressant in vivo.
Technical Data for Roxindole hydrochloride
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Roxindole hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||19.15||50 with gentle warming|
Preparing Stock Solutions for Roxindole hydrochloride
The following data is based on the product molecular weight 382.93. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.22 mL||26.11 mL||52.23 mL|
|2.5 mM||1.04 mL||5.22 mL||10.45 mL|
|5 mM||0.52 mL||2.61 mL||5.22 mL|
|25 mM||0.1 mL||0.52 mL||1.04 mL|
Product Datasheets for Roxindole hydrochloride
References for Roxindole hydrochloride
References are publications that support the biological activity of the product.
Bartoszyk et al (1996) Roxindole: psychopharmacological profile of a DA D2 autoreceptor agonist. J.Pharmacol.Exp.Ther. 276 41 PMID: 8558454
Newman-Tancredi et al (1999) Actions of roxindole at recombinant human DA D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch.Pharmacol. 359 447 PMID: 10431754
Seyfried et al (1989) Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D-2 DA agonist with actions on serotonin systems. Eur.J.Pharmacol. 160 31 PMID: 2565817
If you know of a relevant reference for Roxindole hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Roxindole hydrochloride, Roxindole hydrochloride supplier, 5-HT, reuptake, inhibitors, inhibits, affinity, 5-HT1A, receptors, D2, dopamine, dopaminergic, agonists, autoreceptor, D3, D4, transporters, Serotonin, 5-HT-, 5-Hydroxytryptamine, Receptors, D2-like, Non-Selective, EMD49980, EMD, 49980, Non-selective, Dopamine, 5-HT-Related, 1559, Tocris Bioscience
Citations for Roxindole hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Roxindole hydrochloride. Do you know of a great paper that uses Roxindole hydrochloride from Tocris? Please let us know.
Reviews for Roxindole hydrochloride
There are currently no reviews for this product. Be the first to review Roxindole hydrochloride and earn rewards!
Have you used Roxindole hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.